Latest Period
Q1 2026
Security Snapshot
Cardiff Oncology, Inc. - Common Stock (CRDF) Institutional Ownership
CUSIP: 14147L108
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
114
Shares (Excl. Options)
24,535,304
Price
$1.62
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CRDF on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 24,535,304
- Total 13F value
- $39,578,405
- Portfolio coverage rank
- 0%
- Share change
- -2,701,186
- Value change
- -$5,388,927
- Number of holders
- 114
- Shares outstanding
- 66,577,393
- SEC-reported price per share
- $1.69
- Insider filing price
- $1.69
Latest holder snapshot
5 signals
Issuer context
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CRDF - Cardiff Oncology, Inc. - Common Stock is tracked under CUSIP 14147L108.
- 114 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 109 to 114 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $76,560,088 to $39,578,405.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 114 institutions filings for Q1 2026.
Security key
14147L108
Latest holder period
Q1 2026
13F holders
114
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
CRDF full holder history
Cardiff Oncology, Inc. SEC filings
Cardiff Oncology, Inc. company facts
Cardiff Oncology, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 14147L108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
CRDF
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.8% | +38% | $10,678,250 | +$2,780,523 | 3,841,097 | +35% | BlackRock, Inc. | 31 Mar 2025 |
| PFIZER INC | 3.6% | $6,704,178 | 2,411,575 | Pfizer Inc. 13-5315170 | 31 Dec 2024 |
As of 31 Mar 2026, 114 institutional investors reported holding 24,535,304 shares of Cardiff Oncology, Inc. - Common Stock (CRDF). This represents 37% of the company’s total 66,577,393 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
34%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6% | 3,981,387 | -1.5% | 0% | $6,449,847 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 2,855,966 | 0% | 0% | $4,626,665 |
| Laurion Capital Management LP | 4% | 2,646,738 | 0% | 0.4% | $4,287,716 |
| Pfizer Inc | 3.6% | 2,411,575 | 0% | 1.6% | $3,737,941 |
| ACORN CAPITAL ADVISORS, LLC | 2.6% | 1,762,084 | -10% | 0.81% | $2,854,576 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 1,599,663 | +5% | 0% | $2,592,106 |
| FRANKLIN RESOURCES INC | 1.8% | 1,205,803 | 0% | 0% | $1,953,401 |
| STATE STREET CORP | 1.8% | 1,186,947 | -0.39% | 0% | $1,922,854 |
| BLAIR WILLIAM & CO/IL | 1.4% | 922,407 | -53% | 0% | $1,494,299 |
| FLPUTNAM INVESTMENT MANAGEMENT CO | 0.89% | 595,127 | -0.03% | 0.01% | $964,106 |
| NORTHERN TRUST CORP | 0.74% | 493,205 | +6.8% | 0% | $798,993 |
| VANGUARD FIDUCIARY TRUST CO | 0.67% | 446,225 | 0% | 0% | $722,885 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.66% | 437,214 | 0% | 0% | $708,287 |
| UBS Group AG | 0.6% | 400,576 | +358% | 0% | $648,934 |
| Bank of New York Mellon Corp | 0.46% | 303,428 | -7.8% | 0% | $491,552 |
| XTX Topco Ltd | 0.38% | 250,222 | +14% | 0.01% | $405,360 |
| TWO SIGMA INVESTMENTS, LP | 0.31% | 206,990 | -71% | 0% | $335,324 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.25% | 164,708 | -13% | 0% | $266,827 |
| Avestar Capital, LLC | 0.2% | 136,145 | 0% | 0.02% | $220,555 |
| GOLDMAN SACHS GROUP INC | 0.2% | 135,598 | -65% | 0% | $219,669 |
| Nuveen, LLC | 0.2% | 130,346 | +62% | 0% | $211,161 |
| CITADEL ADVISORS LLC | 0.19% | 125,566 | +6.2% | 0% | $203,417 |
| GSA CAPITAL PARTNERS LLP | 0.18% | 123,008 | -42% | 0.01% | $199,000 |
| AlphaCore Capital LLC | 0.16% | 108,426 | -5.2% | 0% | $175,650 |
| RENAISSANCE TECHNOLOGIES LLC | 0.15% | 101,253 | 0% | $164,030 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 24,535,304 | $39,578,405 | -$5,388,927 | $1.62 | 114 |
| 2025 Q4 | 27,249,041 | $76,560,088 | +$6,436,504 | $2.81 | 109 |
| 2025 Q3 | 25,201,266 | $51,916,152 | -$9,684,486 | $2.06 | 111 |
| 2025 Q2 | 28,660,334 | $90,269,224 | -$11,262,615 | $3.15 | 114 |
| 2025 Q1 | 32,345,011 | $101,559,895 | +$10,196,300 | $3.14 | 116 |
| 2024 Q4 | 28,092,578 | $121,918,732 | +$50,159,924 | $4.34 | 117 |
| 2024 Q3 | 12,761,449 | $34,074,638 | -$895,795 | $2.67 | 82 |
| 2024 Q2 | 13,089,737 | $29,054,064 | +$5,567,075 | $2.22 | 90 |
| 2024 Q1 | 8,576,486 | $45,797,587 | +$17,940,647 | $5.34 | 74 |
| 2023 Q4 | 5,309,425 | $7,858,363 | -$215,046 | $1.48 | 55 |
| 2023 Q3 | 5,456,265 | $7,583,910 | -$756,925 | $1.39 | 55 |
| 2023 Q2 | 5,991,988 | $8,808,700 | -$1,673,969 | $1.47 | 50 |
| 2023 Q1 | 7,049,719 | $11,633,255 | -$748,502 | $1.65 | 52 |
| 2022 Q4 | 7,699,341 | $10,776,288 | -$189,952 | $1.40 | 55 |
| 2022 Q3 | 7,924,242 | $12,205,032 | -$1,956,121 | $1.54 | 47 |
| 2022 Q2 | 8,925,020 | $19,636,792 | -$17,827,128 | $2.20 | 54 |
| 2022 Q1 | 16,524,301 | $40,953,207 | -$30,166,620 | $2.48 | 81 |
| 2021 Q4 | 22,015,576 | $132,083,136 | +$5,192,808 | $6.01 | 81 |
| 2021 Q3 | 21,121,086 | $140,722,888 | -$35,953,961 | $6.66 | 82 |
| 2021 Q2 | 26,525,986 | $176,397,333 | +$10,825,969 | $6.65 | 81 |
| 2021 Q1 | 24,079,194 | $222,960,463 | -$69,848,932 | $9.26 | 70 |
| 2020 Q4 | 26,636,620 | $479,141,900 | +$144,188,615 | $17.99 | 79 |
| 2020 Q3 | 18,710,542 | $265,500,071 | +$207,902,213 | $14.19 | 63 |
| 2020 Q2 | 4,923,525 | $24,668,025 | +$24,668,026 | $5.01 | 23 |